Refer to the PDF below for Harbor Specific Management
https://wikem.org/wiki/File:Non-occupational_Post-Exposure_Prophylaxis_(nPEP)_for_HIV_Prevention_in_Adults_and_Adolescents_Expected_Practice.pdf
https://wikem.org/wiki/File:Non-occupational_Post-Exposure_Prophylaxis_(nPEP)_for_HIV_Prevention_in_Adults_and_Adolescents_Expected_Practice.pdf
NOT recommended
PEP should be started as soon as possible after significant<unk>  and continued for 28 days
Raltegravir (Isentress; RAL) 400 mg PO twice daily, plus
Truvada, 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg)
Other Considerations
If known source patient with resistant<unk>  strain, consult<unk>  service for source-patient-specific PEP
Consider interactions with current medication interactions and contraindications, such as renal impairment with Truvada
For patients with creatinine clearance <60mL/min, consider Raltegravir 400mg PO twice daily, plus Zidovudine and Lamivudine with doses adjusted to the degree of renal dysfunction.
If the  source<unk>   does  report<unk>   to<unk>   within the  last  6 weeks,<unk>   RNA  PCR <unk>   viral  load)  should be  sent  along  with<unk>   Ag/Ab screen on  the  source  and nPEP  should be  initiated for  the  exposed patient
If  both tests  result  not  detected  and nonreactive, respectively, nPEP  should  be  discontinued.
If the  source  is  willing  and  able  to be  tested and is  found to be <unk> -negative with  no  recent high-risk<unk> s  to<unk> , nPEP  is  not  indicated  and  should not  be  initiated, or  discontinued if  already  started.
The exposed  patient  still  warrants  baseline<unk>   testing  and  should  be offered  baseline  and follow-up testing  for  other  transmissible  infections,  e.g. hepatitis  A, B, and C, syphilis, chlamydia, and gonorrhea.
For patients with creatinine clearance <60mL/min, consider Raltegravir 400mg PO twice daily, plus Zidovudine and Lamivudine with doses adjusted to the degree of renal dysfunction.
If  both tests  result  not  detected  and nonreactive, respectively, nPEP  should  be  discontinued.
If the  source  is  willing  and  able  to be  tested and is  found to be <unk> -negative with  no  recent high-risk<unk> s  to<unk> , nPEP  is  not  indicated  and  should not  be  initiated, or  discontinued if  already  started.
The exposed  patient  still  warrants  baseline<unk>   testing  and  should  be offered  baseline  and follow-up testing  for  other  transmissible  infections,  e.g. hepatitis  A, B, and C, syphilis, chlamydia, and gonorrhea.
"Expert consultation should be sought in all cases"
HIV post-exposure prophylaxis
Ritonavir-boosted nirmatrelvir
COVID-19 Vaccine 
Ritonavir
Molnupiravir
Abacavir/lamivudine
Isolation precautions
Emtricitabine/tenofovir